Join
Live feed
·
PRReleasevia Quantisnow
Merus N.V. logo

Merus' Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)

ByQuantisnow·Wall Street's wire, on your screen.
MRUS· Merus N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRUS (Merus N.V.) and more on Quantisnow.